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High-mobility group box-1 (HMGB1) protein has been postulated to play a path-
ogenic role in severe sepsis. Histidine-rich glycoprotein (HRG), a 75 kDa plasma
protein, was demonstrated to improve the survival rate of septic mice through
the regulation of neutrophils and endothelium barrier function. As the relation-
ship of HRG and HMGB1 remains poorly understood, we investigated the effects
of HRG on HMGB1-mediated pathway in endothelial cells, focusing on the
involvement of specific receptors for HRG. HRG potently inhibited the HMGB1
mobilization and effectively suppressed rHMGB1-induced inflammatory re-
sponses and expression of all three HMGB1 receptors in endothelial cells. More-
over, we first clarified that these protective effects of HRG on endothelial cells
were mediated through C-type lectin domain family 1 member A (CLEC-1A) re-
ceptor. Thus, current study elucidates protective effects of HRG on vascular
endothelial cells through inhibition of HMGB1-mediated pathways may
contribute to the therapeutic effects of HRG on severe sepsis.
INTRODUCTION
High-mobility group box-1 (HMGB1), a nonhistone chromatin-binding nuclear protein, can be actively
secreted into the extravascular space by several immune cell types or passively released by damaged tis-
sues and necrotic cells (DeMarco et al., 2005; Andersson et al., 2000). A high concentration of HMGB1 in the
plasma of patients with severe sepsis correlates with a poor prognosis and high mortality, and the pharma-
cologic inhibition of HMGB1 improved survival in animal models of acute inflammation and severe sepsis
(Chen et al., 2004). Systemic inflammation is one of the hallmarks of septic shock, and the disorder of micro-
vascular endothelium appears to produce the amplification of these inflammatory responses (Kirkpatrick
et al., 1997). Thus, microvascular injury is one of the characteristics of sepsis-associated tissue damage
that may be manifested by single or multiple organ failure syndromes (Lehr et al., 2000; Lentsch and
Ward, 2000). HMGB1 was reported to have multiple proinflammatory effects on vascular endothelial cells
by binding to three pathogen-associated cell surface pattern recognition receptors, thereby inducing tu-
mor necrosis factor alpha (TNF-a) expression and NF-kB activation in target cells and stimulating the pro-
duction of an array of proinflammatory cytokines (Abraham et al., 2000; Park et al., 2004; Lotze and Tracey,
2005; Fiuza et al., 2003; Treutiger et al., 2003; Mullins et al., 2004), which suggest an important role for
HMGB1 in endothelial cell activation and injury in sepsis and systemic inflammation.
Histidine-rich glycoprotein (HRG) is an abundant plasma protein (60–100 mg/mL) synthesized in liver,
which can regulate many biological processes such as angiogenesis, coagulation, and the phagocytosis
of apoptotic cells through the interaction with various ligands (Koide et al., 1986; Ronca and Raggi, 2015;
Poon et al., 2011). Shannon et al. proved that HRG decreased the mortality of a septic mouse model with
S pyogenes-induced abscesses by killing and trapping bacteria in the abscess sites (Shannon et al., 2010).
Wake et al. reported that HRG prevents septic lethality through the regulation of neutrophils and vascular
endothelial cells (Wake et al., 2016). A counteracting role of HRG on damage-associated molecular
pattern/pathogen-associated molecular pattern (DAMP/PAMP)-induced responses has long been recog-
nized (Wake et al., 2009, 2016; Gao et al., 2019; Zhong et al., 2018). In recent clinical studies, HRG was also
proposed as a new biomarker to predict the outcome of sepsis patients (Kuroda et al., 2018; Nishibori
et al., 2018). However, the effect of HRG on HMGB1 release or HMGB1 signaling has never beeniScience 23, 101180, June 26, 2020 ª 2020 The Authors.
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Figure 1. HRG Inhibited LPS-induced HMGB1 Translocation and Release in EA.hy926 Cells
(A) EA.hy926 cells were stimulated with the indicated concentrations of LPS for indicated time, and the translocation of HMGB1 was observed by
immunostaining as described in the Methods section. HMGB1 staining (green) and nucleus staining (blue) fluorescence are shown.
(B) EA.hy926 cells were incubated with different concentrations of HRG or PBS for 1 h before being stimulated with 100 ng/mL LPS for 12 h. See also
Figure S1–S3.
(C) The quantification results of nuclear HMGB1 using ImageJ software. The results shown are the means G SEM of five determinations.
(D) EA.hy926 cells were stimulated with the indicated concentrations of LPS for 12 h (left panel), and the HMGB1 in the cytosol and nucleus was determined
by western blotting. The LPS (100 ng/mL)-induced HMGB1 translocation was determined under different concentrations of HRG (right panel). The cytosolic
and nuclear extracts were prepared with NE-PER extraction reagents, and the content of HMGB1 was measured by western blotting. The results were
quantified by ImageJ software and are expressed as the ratio of cytosol/nuclei HMGB1.
(E) Endothelial cells were cultured for 12 h with LPS (100 ng/mL) in the presence or absence of HRG. The cell lysates and the supernatants were collected and
analyzed for HMGB1 by western blotting.
See also Figure S4. All results are the means G SEM of five different experiments. Scale bars, 5 mm. One-way ANOVA followed by the post hoc Fisher test.




Articleinvestigated. It is possible that HRG as a ligand-like molecule may exert its cellular function through the
stimulation of unidentified receptors on endothelial cells.
C-type lectin-like receptors (CLECs) comprise a diverse family of transmembrane pattern recognition re-
ceptors that are expressed primarily on myeloid cells (Colonna et al., 2000), and CLECs are now considered
driving players of sterile inflammation whose dysregulation leads to the development of various pathol-
ogies such as autoimmune diseases, allergy, and cancer (Chiffoleau, 2018). CLEC-1A is an orphan type II
transmembrane receptor of the C-type lectin superfamily, which is expressed by dendritic cells and endo-
thelial cells in humans (Colonna et al., 2000; Chiffoleau, 2018; Sobanov et al., 2001; Kanazawa, 2007). CLEC-
1A triggering may directly modulate the activation of the dendritic cells and endothelial cells and/or send a
regulatory signal to T cells (Sattler et al., 2012; Lopez Robles et al., 2017). Therefore, CLEC-1A may be a
useful target to modulate immune responses toward protective immunity.
In present study, we firstly proved that the inhibitory effects of HRG on lipopolysaccharide (LPS)-induced
HMGB1 translocation and HMGB1-induced signal pathway were mediated through the stimulation of spe-
cific receptors of CLEC-1A on vascular endothelial cells. Our results strongly suggest that the inhibition of
HMGB1 action by HRG may contribute to HRG’s mortality-reducing protective activity against severe
sepsis, and our findings also further explained the mechanism underlying the regulation of neutrophils
and endothelium barrier function by HRG under septic conditions in vivo and in vitro (Wake et al., 2016;
Gao et al., 2019). This demonstration of an intimate relationship between HRG and HMGB1 provides direct
supporting evidence for the supplementary treatment of sepsis with HRG.
RESULTS
HRG Inhibited LPS-induced HMGB1 Translocation and Release in Endothelial Cells
Several studies showed that HMGB1 can be released from human endothelial cells in response to both
endotoxin and TNF-a (Fiuza et al., 2003; Treutiger et al., 2003; Mullins et al., 2004). EA.hy926 is a trans-
formed cell line, established by fusing primary human umbilical vein endothelial cells with a thioguanine-
resistant clone of A549, carcinoma of human alveolar epithelial cell. Our results showed that LPS actively
induced HMGB1 translocation from EA.hy926 cells in a concentration- and time-dependent manner (Fig-
ure 1A), whereas HRG inhibited this process in a concentration-dependent manner (Figure 1B, left
panel). However, HSA, a major plasma protein, did not show any inhibitory effects at the same concen-
tration (1 mmol/L). In addition, HRG did not show any influence on HMGB1 translocation in the absence
of LPS (Figure 1B, right panel). These results were quantified with ImageJ software through the setting of
a cutoff level of HMGB1 fluorescence in the cell nuclei (Figure 1C). HRG also inhibited the TNF-
a-induced HMGB1 translocation in EA.hy926 cells (Figure S1). The inhibition effect of HRG on LPS-
induced HMGB1 translocation was also true in primary human lung microvascular endothelial cells
(HMVECs, Figure S2).
To confirm these results, we also measured the HMGB1 content in nucleus, cytoplasma, and culture me-
dium of endothelial cells with western blotting. The results showed that HRG not only inhibited HMGB1
translocation from nucleus to cytoplasma (Figure 1D) but also effectively suppressed HMGB1 release
into extracellular space (Figure 1E). The cell viability assay also proved that the LPS stimulation triggered
an active release of HMGB1 from EA.hy926 cells and both LPS (100 ng/mL) and rHMGB1 (1 mg/mL) were notiScience 23, 101180, June 26, 2020 3
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Figure 2. HRG Suppressed the rHMGB1-Mediated Adhesive Molecule Expression and Neutrophils Adhesion on EA.hy926 Cells
(A and B) Confluent EA.hy926 cells were incubated with rHMGB1 (1 mg/mL for 16 h) after being treated with HRG or HSA for 1 h. The cell surface expression of
(A) VCAM-1 (green) and (B) ICAM-1 (red) on the cells was observed by immunostaining. See also Figure S5.
(C) Positive cells were counted in six fields of each group.
(D) A confluent endothelial monolayer was incubated with LPS (100 ng/mL) or rHMGB1 (1 mg/mL) in the presence or absence of HRG, and the amount of
neutrophils that adhered to the endothelial monolayer was measured.
(E) The data are the percentage of neutrophil numbers compared with those in PBS.
The results shown are the means G SEM of three experiments. Scale bars, 20 mm. One-way ANOVA followed by the post hoc Fisher test. **p < 0.01 versus




Articletoxic to the endothelial cells (Figure S3). In addition, HRG effectively inhibited the LPS-induced decrease in
HMGB1 mRNA expression in both EA.hy926 cells and HMVECs (Figure S4).HRG Suppressed the rHMGB1-Mediated Adhesive Molecule Expression and Neutrophil
Adhesion
HMGB1 was reported to induce inflammatory responses by increasing the cell surface expressions of the
cell adhesion molecules ICAM-1, VCAM-1, and E-selectin on the surface of endothelial cells, thereby pro-
moting the adhesion and migration of leukocytes across the endothelium and to sites of inflamed tissues
(Fiuza et al., 2003; Treutiger et al., 2003; Mullins et al., 2004). As presented in Figures 2A–2C, HRG effectively
inhibited rHMGB1-induced expressions of ICAM-1 and VCAM-1. These effects of HRG were also observed
in primary human lung microvascular endothelial cells (Figure S5).
As is well known, elevated expressions of adhesion molecules correlate well with the enhanced binding of neu-
trophils to endothelial cells and their subsequentmigration.We therefore performed cell adhesion experiments
using purified neutrophils and endothelial cell co-culture system. The results showed that HRG inhibited the
adhesion of human neutrophils to both LPS- and rHMGB1-activated endothelial cells (Figures 2D and 2E).HRG Prevented the rHMGB1-induced Inflammatory Responses
Cytokine overproduction is one of the major events in severe inflammatory responses. Released HMGB1 is
known to interact with specific cell receptors to amplify inflammatory responses by inducing the expression of
proinflammatory cytokines (Fiuza et al., 2003; Treutiger et al., 2003; Mullins et al., 2004). According to RT-PCR
results in Figure 4A (upper panel), the 12-h incubation of EA.hy926 cells with different concentrations of rHMGB1
resulted in concentration-dependent expressions of TNF-a and NF-kB. HRG (1 mM) strongly inhibited rHMGB1
(1 mg/mL)-induced responses. In addition, HRG significantly inhibited the rHMGB1-induced increase in the ex-
pressions of IL-6, IL-8, and IL-1b (Figure 3A) and cytokine secretion in the culture medium (Figure 3B).
HMGB1 was reported to upregulate inflammatory pathways by activating NF-kB and promoting the
expression of TNF-a by endothelial cells andmonocytes (Andersson et al., 2000). As presented in Figure 4A,
NF-kB/p65 was localized mainly in the cytoplasm in the non-stimulated control group, whereas in the
rHMGB1-treated cells, NF-kB/p65 was translocated into the nuclei. Pretreatment with HRG clearly sup-
pressed the rHMGB1-induced NF-kB/p65 translocation to nuclei in endothelial cells in immunostaining
and western blotting (Figures 4A and 4B). The effects of HRG on the NF-kB activation were consistent
with HRG’s effects on the rHMGB1-induced cytokine production.HRG Downregulates the Expression of HMGB1 Receptors
The pro-infiammatory activity of rHMGB1 was reported to be mediated via its interaction and subsequent
signaling through TLR2, TLR4, and RAGE (Park et al., 2004). As shown in Figure 4C, rHMGB1 induced the
mRNA expression of all three receptors in endothelial cells by 1.7- to 2.4-fold, and HRG significantly in-
hibited the stimulatory effects of rHMGB1 on the expressions of TLR2, TLR4, and RAGE. Similar effects
on their protein levels were also shown by western blotting (Figure 4D). These results demonstrated that
one of the action mechanisms of HRG depends mainly on the suppression of the receptors’ overexpression
on endothelial cells induced by rHMGB1.HRG Inhibited HMGB1 Release and HMGB1-Mediated Inflammatory Responses In Vivo
To further confirm the relationship of HRG and HMGB1, we also examined the role of HRG on the regula-
tion of HMGB1 release and rHMGB1-mediated signals in vivo. Previous study showed that plasma HRGiScience 23, 101180, June 26, 2020 5
Figure 3. HRG Inhibited the rHMGB1-Stimulated Expression and Secretion of Proinflammatory Mediators in
Endothelial Cells
EA.hy926 cells were cultured with rHMGB1 (1 mg/mL) for 12 h in the presence or absence of HRG (1 mM).
(A) The mRNA expressions of TNF-a, NF-kB, IL-1b, IL-6, and IL-8 in the cells were measured by quantitative RT-PCR. The
results were normalized to the expression of b-actin and are expressed as the means G SEM (n = 5 per group).
(B) Cell-free supernatants were harvested after 12-h stimulation with rHMGB1 to measure the concentrations of different
proinflammatory cytokines by a CBA assay. The levels of IL-6, IL-8, and TNF-a in the culture media from each group are
shown as the mean G SEM (n = 5 per group). One-way ANOVA followed by the post hoc Fisher test. **p < 0.01 versus
control, ##p < 0.01 and ++p < 0.01 vs. PBS and HSA.
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Figure 4. HRG Suppressed the rHMGB1-induced NF-kB Activation and Receptors Expressions in Endothelial Cells
(A) Immunostaining results of NF-kB in endothelial cells stimulated with 1 mg/mL rHMGB1 for 6 h after treatment with HRG or HSA. Cells were stained with
anti-NF-kB/p65 mAb for 2 h and then stained with Alexa Fluor 488 (green)-labeled goat-anti-rabbit IgG. Cells were also stained with DAPI (blue) to visualize
the nuclei. The results are representative of R5 experiments. Scale bar, 10 mm.
(B) Cytosolic and nuclear extracts were prepared with NE-PER extraction reagents, and the levels of NF-kB/p65 were determined by western blotting. The
results were quantified by ImageJ software.
(C) Confluent endothelial cells were incubated with rHMGB1 (1 mg/mL for 16 h) with or without pretreatment with HRG (1 mM) for 1 h. The expressions of TLR2,
TLR4, and RAGE in the cells were measured by RT-PCR. The results were normalized to the expression of b-actin and are expressed as the meansG SEM (n =
5 per group).
(D) The protein levels of these receptors were also determined by western blotting. The results were quantified with ImageJ software. All results aremeansG





Articledramatically decrease in septic or LPS-induced endotoxemia mice (Wake et al., 2016). Our results in Fig-
ure 5A proved that not only LPS- but also rHMGB1-injected mice showed obvious reduction of plasma
HRG in mice. HMGB1 is a late mediator of endotoxin lethality in mice (Wang et al., 1999). Supplementary
treatment with HRG in LPS-injected mice showed inhibition effects on the production of plasma HMGB1
(Figure 5B). Moreover, HRG significantly suppresses the elevated proinflammatory cytokine TNF-a and
IL-1b in rHMGB1-injected mice (Figure 5C). These results proved that HRG also can regulate the HMGB1
release and HMGB1-mediated inflammatory responses in vivo.
CLEC-1A Was Identified as the Receptor for HRG
In light of the multi-gene families of candidate receptors, we selected 18 genes (CLEC-1A, -1B, -2A, -2B,
-2C, -2D, -4A, -4C, -4D, -4E, -4F, -4G, -4M, -5A, -6A, -7B, -12A, and -12B) from the CLEC family, two genes
(TREM-1 and -4) from the TREM (triggering receptor expressed on myeloid cells) family, and five genes (SI-
GLEC-3, -5, -9, -14, -15) from the SIGLEC (sialic acid-binding Ig type lectin [SIGLEC]) family in accord with
our interest in HRG binding. The individual genes were examined for HRG interaction. After the dual trans-
fection of maHRG with each receptor plasmid to HEK293T cells, we examined the maHRG co-immunopre-
cipitates from the transfected cell lysates by western blotting to evaluate the potential binding of maHRG
with the foreign receptors. The results indicated that one event of interaction clearly occurred in the
screening trial using a CLEC family member, i.e., CLEC-1A (Figure 6A). We observed no appreciable inter-
action with the TREM or SIGLEC family members (data not shown). Collectively, these results prompted us
to focus on CLEC-1A as a novel receptor for HRG.
The BIAcore sensograms of both exCLEC-1A-Fc and human recombinant exCLEC-1A protein to immobi-
lized HRG showed a rapid increase in response units (RUs), indicating the binding of both exCLEC-1A-Fc
fusion protein and human recombinant exCLEC-1A protein to the immobilized HRG on the chip, followed
by a decrease in the RU resulting from the dissociation of binding molecules upon washing. The binding of
exCLEC-1A-Fc fusion protein and human recombinant exCLEC-1A protein to HRG was concentration
dependent (Figures 6B and S6A). The equilibrium dissociation constant (KD) was determined as 7310
9
M and 43107, respectively. These results thus suggested a high-affinity binding of HRG to CLEC-1A.
Meanwhile, when the exCLEC-1A-Fc fusion protein was immobilized on the CM5 sensor chip, the BIAcore
sensogram of HRG to immobilized exCLEC-1A-Fc also showed a concentration-dependent increase in
response units (Figure S6B). The equilibrium dissociation constant (KD) was determined as 1310
8 M.
These results demonstrate a high-affinity binding of HRG to CLEC-1A in both directions.
Blocking of CLEC-1A Neutralizes the Protective Activity of HRG on Neutrophils and
Endothelial Cells
It was reported that HRG (1 mmol/L) maintained the spherical shape of neutrophils, sustaining the rheological
stability and preventing the unnecessary activation of vascular endothelial cells (Wake et al., 2016). We observed
themorphological changes of the neutrophils under a fluorescentmicroscope at 60min after incubation without
a fixation procedure. Compared with the HBSS group, these neutrophils treated with HRG had a spherical
shape, a loss of the irregularity of shapes, and shortened diameters. However, the spherical shape-inducing ef-
fects of HRG were significantly neutralized by the treatment with exCLEC-1A-Fc fusion protein (Figure 6C-a) or
CLEC-1A Ab (Figure 6D-a), accompanied with increase of Form factor and cell area (Figures 6C-b and 6D-b).
The western blotting and RT-PCR results established that CLEC-1A was expressed in EA.hy926 cells. The
expression level of CLEC-1Awas not changed after stimulation with LPS (Figure 7A). The experiment results8 iScience 23, 101180, June 26, 2020
Figure 5. HRG Inhibited HMGB1 Release and HMGB1-Mediated Inflammatory Responses In Vivo
C57BL/6N mice was intravenous injected of LPS (10 mg/kg) or recombinant HMGB1 (100 mg) and then HRG or HSA in
vehicle (PBS) was administered through the tail vein immediately. Each mouse was given 20 mg/kg HRG or HSA in a
volume of 200 mL (IV). After 12 h the whole blood from mouse heart was taken and centrifuged for 10 min at 3,000 rpm to
obtain the plasma.
(A) Plasma levels of HRG in mice were determined 12 h after LPS (10 mg/kg) or rHMGB1 (100 ug/mouse) injection by
western blotting. The relative expression levels were calculated as percentage of sham control.
(B) HMGB1 levels in plasma were measured in LPS-injected mice (12 h) by ELISA.
(C) Proinflammatory cytokine TNF-a and IL-1b were measured 12 h after rHMGB injection in mice with cytokine beads
assay. N = 6, one-way ANOVA followed by the post hoc Fisher test. **p < 0.05 versus Sham, ##p < 0.05 and ++p < 0.05




Articlein Figure 7 confirmed that the inhibitory effects of HRG on the LPS-induced HMGB1 translocation and
rHMGB1-stimulated ICAM-1 expression in EA.hy926 cells were clearly neutralized by the pre-incubation
with CLEC-1A Ab (10 mg/mL) for 6 h (Figures 7B and 7C). In addition, CLEC-1A or CLEC-1B Ab alone did
not show any effects on the LPS-induced activation of endothelial cells (Figures 7B and 7C) or regulation
of morphology changes of neutrophils (Figure 6D). These results provide evidence that CLEC-1A may
be one of the receptors of HRG0 s action on neutrophils and endothelial cells.
DISCUSSION
HMGB1 plays a novel inflammatory cytokine-like role that contributes to the lethality of sepsis, and neutral-
izing of HMGB1 release protected animals from the lethality of endotoxemia (Sama et al., 2004; Wang et al.,
1999, 2001). The results presented herein together with those reported by others (Fiuza et al., 2003;iScience 23, 101180, June 26, 2020 9
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Figure 6. The Identification of CLEC-1A Receptor for HRG
(A) HEK293T cells were transiently transfected with the plasmid vector of maHRG combined with each vector encoding a series of collected receptors, using
FuGENE-HD. The collected receptors contained CLEC-1A, -1B, -2A, -2B, -2C, -2D, -4A, -4C, -4D, -4E, -4F, -4G, -4M, -5A, -6A, -7B, -12A, and -12B. After 24 h of
the transfection, cell pellets were prepared and lysed byM-PERmammalian protein extraction reagent. The lysates were then incubated with agarose beads
conjugated with monoclonal anti-HA tag antibody to pull-down the expressed maHRG. The resulting immunoprecipitates were then subjected to western
blotting using monoclonal anti-Flag tag antibody to detect maHRG-bound receptor candidate(s).
(B) The binding affinity of CLEC-1A-Fc to HRG in vitro. Purified HRG (5 mg/mL) from human plasma was immobilized on a CM5 BIAcore chip, and different
concentrations of the extracellular domain of CLEC-1A-Fc (exCLEC-1A-Fc) fusion protein (3.125, 6.25, 12.5, or 25 mg/mL) were flowed at time zero for 120 s.
Surface plasmon resonance (BIAcore) showed a rapid increase in response units (RU), indicating the binding of exCLEC-1A-Fc fusion protein to the
immobilized HRG. The KD for exCLEC-1A-Fc binding to HRG was determined as 7310
9 M. See also Figure S6.
(C and D) Purified human neutrophils were labeled with calcein-AM (green) and Hoechst33342 (blue) for 20min. The neutrophils were incubated with HBSS or
HRG (0.25 mM) together with different concentrations of exCLEC-1A-Fc fusion protein (1–30 mg/mL) or 10 mg/mL CLEC-1A Ab or CLEC1B Ab for 1 h, and the
neutrophil shapes were observed by fluorescence microscopy. (a) Typical picture of fluorescence staining from each group; scale bars, 20 mm. (b) The shapes
and sizes of neutrophils were analyzed by an IN Cell Analyzer 2000. The Form factor (max. dia./min. dia.) and cell area (mm2) were determined. One unit
represents an ideal spherical shape of neutrophils in the Form factor. The results are the means G SEM of five experiments. **p < 0.01 versus control and




ArticleTreutiger et al., 2003; Mullins et al., 2004) suggest that vascular endothelial cells may be rich sources of
HMGB1. Released HMGB1 activates endothelial cells by upregulating its surface receptors. It was also re-
ported that recombinant HMGB1 had potent proinflammatory activity on vascular endothelial cells (Bae
and Rezaie, 2011; Degryse et al., 2001). Therefore, the modulation of the release of HMGB1 from endothe-
lial cells and the regulation of released HMGB1-mediated signal pathways in endothelial cells may provide
a novel means of treating acute inflammatory conditions, especially in sepsis.
Clinical studies revealed that the plasma HRG levels of septic patients were significantly lower than those of
healthy subjects (Kuroda et al., 2018; Nishibori et al., 2018). Wake et al. demonstrated that supplementary
treatment with HRG can effectively improve the survival rate of septic mice and relieve their inflammatory
syndrome (Wake et al., 2016). Our previous study established that HRG has a potent protective activity on
vascular endothelium barrier function under septic condition (Gao et al., 2019). Nevertheless, the effects of
HRG on HMGB1 release and HMGB1-mediated proinflammatory responses in vascular endothelial cells
had not been studied prior to the present investigation.
Our present findings showed that HRG effectively inhibited LPS-induced HMGB1 translocation from nu-
cleus to the cytoplasm and subsequently to the extracellular space (Figure 1). Although HMGB1 can be
passively released after necrosis, our results demonstrated that the LPS-induced translocation and release
of HMGB1 in EA.hy926 cells is independent of cell death. We did not detect any significant increase in cell
apoptosis or necrosis during the stimulation with LPS (Figure S3). In addition, HRG effectively inhibited the
LPS-induced decrease in HMGB1 mRNA expression in both EA.hy926 cells and HMVECs (Figure S4). HRG
alone did not induce any changes in the HMGB1 mRNA expression in the absence of LPS stimulation (Fig-
ure S4). Vascular endothelial cells regulate the inflammatory process through the expression of adhesion
molecules, cytokines, chemokines, and growth factors (Tedgui and Mallat, 2001; Davies et al., 1993; Tedgui
and Mallat, 2006). Endothelial cell adhesion molecules such as VCAM-1 and ICAM-1 are upregulated in
vascular endothelial cells in response to inflammatory stimuli, which in turn mediates leukocyte recruitment
and adherence onto the endothelium (Blankenberg et al., 2003; Figueras-Aloy et al., 2007). The released
HMGB1 can further activate endothelial cells, leading to the upregulation of cell adhesion molecules,
i.e. ICAM-1, VCAM-1, and E-selectin (Fiuza et al., 2003; Treutiger et al., 2003). Herein we proved HRG
also downregulated the rHMGB1-mediated expression of the cell surface adhesion molecules ICAM-1
and VCAM-1 (Figures 2A–2C), thereby inhibiting the adhesion of the neutrophils to the activated endothe-
lial cells (Figures 2D and 2E). Previous studies’ experiments established that HRG effectively regulated neu-
trophils’ activation and immunothrombosis formation in septic mice, and our present results confirmed that
HRG can control the interaction between neutrophils and endothelial cells from both sides.
The inhibition of the production of pro-inflammatory cytokines is a key factor in the prevention and therapy
of sepsis. Extracellular HMGB1 can activate endothelial cells through the activation of NF-kB, leading to
the release of proinflammatory cytokines such as TNF-a and IL-1b (Cohen, 2002). Our results clearly demon-
strated that treatment with HRG can strongly inhibit the rHMGB1-enhanced expression/secretion of IL-8,
IL-6, and TNF-a (Figure 3) and NF-kB activation (Figures 4A and 4B). These findings proved that HRG regu-
late not only the HMGB1 release but also the subsequent inflammatory process induced by extracellular
HMGB1 on endothelial cells. HMGB1 upregulated proinflammatory responses by interacting with threeiScience 23, 101180, June 26, 2020 11
Figure 7. The Inhibitory Effects of Anti-CLEC-1A Antibody on the Protective Activity of HRG on the EA.hy926 Cells
(A) CLEC-1A expression on EA.hy926 cells was confirmed with western blotting and RT-PCR at the protein and mRNA levels. (B, C) EA.hy926 cells were
cultured for 12 h until confluence and then pre-incubated with 10 mg/mL CLEC-1A Ab or CLEC1B Ab or goat IgG control antibody in DMEMmedium for 6 h.
The cells were then stimulated with LPS for 12 h in the presence or absence of HRG (1 mM). The immunostaining of HMGB1 (B) and ICAM-1 (C) were
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performed as described in the Methods section. A representative picture of fluorescence staining from each group is shown; scale bars, 20 mm. The
quantitative results in the graphs are means G SEM (n = 5 per group). One-way ANOVA followed by the post hoc Fisher test. **p < 0.01 versus control,




Articlepathogen-related pattern recognition receptors: TLR2, TLR4, and RAGE. HRG effectively suppressed the
cell surface expression of all three HMGB1 receptors (Figures 4C and 4D) in endothelial cells. These results
provide a likely explanation of how HRG effectively reduces the inflammatory response in rHMGB1-acti-
vated endothelial cells.
HMGB1 was recognized as a latemediator of sepsis, and the neutralization of HMGB1 or the inhibition of its
release protected animals from the lethality of endotoxemia (Sama et al., 2004; Wang et al., 1999, 2001).
Our results show that both LPS and rHMGB1 injection can induce the reduction of HRG in mice plasma (Fig-
ure 5A), suggesting the LPS- or rHMGB1-induced liver injury that influence the HRG production (Tsung
et al., 2005; Gong et al., 2010). The supplementary treatment with HRG can effectively inhibit the
HMGB1 release in LPS-injected mice and reduce inflammatory cytokine production in rHMGB1-injected
mice (Figures 5B and 5C). These results provide a new evidence that HRG improves the survival rate,
and relieve of inflammatory symptom of septic mice may be associated with the regulation of HMGB1
signaling.
A counteracting role of HRG on DAMP/PAMP-induced responses has long been recognized (Wake et al.,
2016; Kuroda et al., 2018; Nishibori et al., 2018). It is possible that HRG as a ligand-like molecule may exert
its cellular function through the stimulation of unidentified receptors. We thus first examined DAMP-
related receptors, i.e., macrophage-inducible C-type lectin (MINCLE) (also known as C-type lectin-like re-
ceptor 4E [CLEC4E]) (Yamasaki et al., 2008), and triggering receptor expressed onmyeloid cells-1 (TREM-1)
(El Mezayen et al., 2007), because ligands for these receptors have not been comprehensively identified,
unlike those of the well-knownDAMP receptors, toll-like receptor 4 (TLR4), and RAGE.We also investigated
SIGLEC family receptors that are key modifiers of neutrophil functions (McMillan et al., 2013; Favier, 2016).
Based on our screening trial using CLEC family members, CLEC-1Awas observed to be the only one among
a set of candidate receptor molecules that interacts with the membrane-anchored HRG that we designed
to be expressed on the cell surface (Figure 6A). The results of our surface plasmon resonance experiments
demonstrated that exCLEC-1A-Fc binds to HRGwith high affinity (KD value of 7310
9 M) (Figure 6B); mean-
while, HRG binds to immobilized exCLEC-1A-Fc with KD value of 1310
8 M (Figure S6B). These results pro-
vide strong evidence that CLEC-1A is one of the receptors for HRG. To further confirm these results, we
examined the protective effect of HRG on neutrophils and endothelial cells after blocking the CLEC-1A.
The results showed that the spherical shape-inducing effects of HRG were significantly neutralized by
the treatment with exCLEC-1A-Fc fusion protein (Figure 6C-a) or CLEC-1A Ab (Figure 6D-a). Moreover, pre-
treatment with CLEC-1A antibody effectively prevented the inhibiting effects of HRG on LPS-induced
HMGB1 translocation (Figure 7B) and HMGB1-mediated ICAM-1 expression (Figure 7C) in EA.hy926 cells.
The neutralizing effect of exCLEC-1A-Fc fusion protein and the blocking effects of CLEC-1A antibody on
the action of HRG on EA.hy926 cells and neutrophils further indicate that CLEC-1Amay be a novel receptor
for HRG.
It is worthy of mentioning that CLEC-1Amight not be the sole receptor for HRG. Our previous study proved
that HRG augmented natural killer cell function by modulating PD-1 expression via CLEC-1B (Nishimura
et al., 2019). Stanniocalcin-2 (STC2) was also reported as an interacting partner of HRG on the surface of
inflammatory cells in vitro. The colocalization of HRG and STC2 in gliomas may play a role for suppressing
glioma growth by modulating tumor inflammation throughmonocyte infiltration and differentiation (Roche
et al., 2018). However, whether the interaction of HRG with STC2 may influence the HRG-CLEC-1A-medi-
ated signaling need to be clarified in the future. HRG is a multidomain protein consisting of 2 N-terminal
regions, a central histidine-rich region (HRR) and a C-terminal domain. HRG interacts with many ligands
through various binding domains, regulating a number of biological processes. Some ligands binding to
the HRR domain of HRG is dependent on Zn2+ or acidic pH (Sundberg and Martin, 1974;; Morgan, 1981).
It should be addressed in the future study, whether HRG-CLEC1A binding is modulated by Zn2+.
The present study is the first report that HRG efficiently inhibited LPS-induced HMGB1 translocation and
release and the HMGB1-mediated signal pathway in vascular endothelial cells through CLEC-1A receptor.




Articleseptic mice can relieve the septic syndrome and prevent endothelium barrier dysfunction. The role of HRG
in barrier protection may depend mainly on its effect of inhibiting HMGB1 release from endothelial cells.
Our results thus not only clarify the receptor of the effects of HRG on vascular endothelial cells but also pro-
vide evidence for HRG as a treatment for sepsis.
Limitation of the Study
We proved the role of HRG on the regulation of HMGB1 signaling in endothelial cells through CLEC-1A
receptor using in vitro experiments. In addition, our previous study found that the knockdown of liver
HRG by siRNA could exacerbate septic inflammation and lethality compared with that in the control
mice, which indicated that the depletion of HRG aremore vulnerable to sepsis (Wake et al., 2016). However,
the involvement of HRG and CLEC-1A in septic condition are not clarified and characterized in vivo in cur-
rent research. Hrg/ and Clec-1A/mice would be used in the future research. Moreover, although we
proved the binding between CLEC 1A and HRG in vitro, the binding domain on HRG and the relationship
with Zn2+ and PH will require additional studies.
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Figure S1. The effects of HRG on the TNF-α-induced HMGB1 translocation in EA.hy 926 
cells, related to Figure 1. EA.hy 926 cells were incubated with HRG or phosphate-buffered saline 
(PBS) for 1 h before being stimulate with 100 ng/ml TNF-α for 12 h, and the translocation of 
HMGB1 was observed by immunostaining as described in the Methods section of the main text. 
HMGB1 staining (green) and nucleus staining (blue) are shown. Images are representative of 




Figure S2. The effects of HRG on the LPS-induced HMGB1 translocation in HMVECs, 
related to Figure 1. Human primary lung microvascular endothelial cells (HMVECs) were 
incubated with HRG or PBS for 1 h before being stimulated with 100 ng/ml LPS for 12 h, and the 
translocation of HMGB1 was observed by immunostaining as described in the Methods section. 
HMGB1 staining (green) and nucleus staining (blue) are shown. Images are representative of 
three independent experiments. Scale bar = 20 μm. The nuclear HMGB1 was quantified using 
ImageJ software. The graph results are means ± SEM (n=5 per group). One-way ANOVA followed 




Figure S3. Cell viability of EA.hy 926 cells after stimulated with LPS or rHMGB1, related to 
Figure 1. EA.hy 926 cells were pre-incubated with HRG/HSA for 1 h before stimulation with LPS 
(100 ng/ml) or rHMGB1 (1 μg/ml) for 8 h. The cells were then incubated with MTT at 37℃ for 4 h 
by adding 10 μl of 5 ng/ml MTT solution into each well. After the removal of the cell supernatant, 
200 μl of DMSO was added into each well to dissolve the crystals. The OD value was recorded 






Figure S4. HRG inhibited the reduction of HMGB1 mRNA expression induced by LPS 
stimulation in EA.hy 926 cells and HMVECs, related to Figure 1. Both lines of vascular 
endothelial cells were cultured with LPS in the presence or absence of HRG. The expression of 
HMGB1 at the mRNA level on the cells was measured by quantitative RT-PCR. The results were 
normalized to the expression of β-actin and are expressed as the means ± SEM (n=5 per group). 
One-way ANOVA followed by the post hoc Fisher test. **p<0.01 vs. control, ##p<0.01 and ++p<0.01 




Figure S5. Effect of HRG on the rHMGB1-induced expression of cell adhesion molecules 
in HMVECs, related to Figure 2. Confluent endothelial cells were incubated with rHMGB1 (1 
μg/ml for 16 h) after being treated with the indicated concentrations of HRG or HSA for 1h. The 
cell surface expression of ICAM-1 (green) on HMVEC was observed by immunostaining. Scale 
bars = 20 μm. 
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Figure S6. HRG and CLEC 1A interaction in vitro unsing Biacore T200, related to Figure 6.  
A: The binding affinity of human recombinant exCLEC-1A protein to HRG in vitro. Purified HRG 
(5 μg/ml) from human plasma was immobilized on a CM5 BIAcore chip, and different 
concentrations of the human recombinant exCLEC-1A protein (3.125, 6.25, 12.5, 25 or 50 μg/ml) 
were flowed at time zero for 120 sec. Surface plasmon resonance (BIAcore) showed a rapid 
increase in response units (RU), indicating the binding of human recombinant CLEC-1A protein 
to the immobilized HRG. The KD value was determined as 4´10−7 M. B: The binding affinity of 
HRG to exCLEC-1A-Fc in vitro. Extracellular domain of CLEC-1A-Fc (exCLEC-1A-Fc) fusion 
protein (10 μg/ml) was immobilized on a CM5 sensor chip, and different concentrations of the 
purified HRG from human plasma (3.125, 6.25, 12.5, 25 or 50 μg/ml) were flowed at time zero for 
120 sec. Surface plasmon resonance (BIAcore) showed a rapid increase in response units (RU), 
indicating the binding of HRG to the immobilized exCLEC-1A-Fc fusion protein. The KD for HRG 
binding to exCLEC-1A-Fc was determined as 1´10−8 M. 
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mRNA            Sense primer                     Anti-sense primer  
β-actin:  5'-AGCGGGAAATCGTGCGTG-3'            5'-CAGGGTACATGGTGGTGCC-3' 
IL-6:  5'-GAACTCCTTCTCCACAAGCGCCTT-3'  5'-CAAAAGACCAGTGATGATTTTCACCAGG-3' 
IL-8:  5'-ATGACTTCCAAGCTGGCCGTGGCT-3'  5'- TCTCAGCCCTCTTCAAAAACTTCTC-3' 
IL-1β:  5'-CAGCCATGCCAGAAGTACCT-3'           5'-GACATCACCAAGCTTTTTTGC-3' 
TNF-α: 5'-GAGTGACAAGCCTGTAGC-3'              5'-CCCTTCTCCAGCTGGAAG-3' 
NF-κBp65:  5'-GCCATGGACGAACTGTTCCCC-3'     5'-GGGAA CAGTTCGTCCATGGC-3' 
TLR-2:  5'-GCCAAAGTCTTGATTGATTGG-3'         5'-TTGAAGTTCTCCAGCTCCTG-3' 
TLR4:  5'-ACTCCCTCCAGGTTCTTGATTAC-3'       5'-CGGGAATAAAGTCTCTGTAGTGA-3' 
RAGE: 5'-GCCCTCCAGTACTACTCTCG-3'           5'-TGTGTGGCCACCCATTCCAG-3' 
CLEC-1A:  5' –AAACAAGAAGACCTGGAATTTGC-3'  5'- TCTTGGGCTGGTGACATCTATTA-3'  




Transparent Methods  
 
Cell cultures 
EA.hy 926 cell line (ATCC Cat# CRL-2922, RRID:CVCL_3901), a hybridoma of human 
umbilical vein endothelial cells (HUVECs) and the adenocarcinomic human alveolar basal 
epithelial cells  A549, were cultured using Dulbecco's modified Eagle medium (DMEM, #D6546, 
Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY), 5% 
L-glutamine (#G7513, Sigma), and 10% penicillin/streptomycin (Gibco) in 5% CO2 at 37°C. After 
reaching confluence, the EA.hy 926 cells were detached from culture flasks using 0.25% Trypsin-
EDTA (Gibco), washed, and resuspended in DMEM. These cells were passaged every 3–4 days, 
and all experiments were performed with the cells kept in culture between three and six passages 
as described (Wake et al., 2016; Gao et al., 2019). 
Primary human lung microvascular endothelial cells (HMVECs) were obtained from Lonza 
(#CC-2527; Walkersville, MD). HMVECs were cultured in EBMTM-2 Basal Medium (#CC-3156, 
Lonza) with the recommended supplements in the EGMTM-2MV SingleQuots Kit (#CC-4147, 
Lonza) in 5% CO2 at 37°C. After reaching confluence, the endothelial cells were detached from 
culture flasks with Accutase® (10 ml per 75 cm2) at 37°C for 10 min, washed, and resuspended in 
culture medium. These cells were passaged every 3–4 days, and all experiments were performed 
with the cells kept in culture between three and ten passages. 
 
Purification of HRG from human plasma 
HRG was purified from human plasma by our lab as described (Mori et al., 2003). Human 
plasma was supplied by the Japanese Red Cross Society from the healthy volunteer’s donation. 
The study protocol complied with the principles outlined in the Declaration of Helsinki and all 
subjects signed an informed consent. Briefly, human plasma was incubated with nickel-
nitrilotriacetic acid (Ni-NTA) agarose (Qiagen, Hilden, Germany) for 2 h at 4°C with gentle shaking. 
The gel was packed into a column and washed successively with 10 mmol/L Tris-buffered saline 
(TBS) (pH 8.0) containing 10 mmol/L imidazole and then 10 mmol/L Tris-buffer (TB) (pH 8.0) 
containing 1 mol/L NaCl. Human HRG was eluted by 0.5 mol/L imidazole in 10 mmol/L TBS (pH 
8.0). The protein eluate from Ni-NTA was further purified by a Mono Q column (GE Healthcare, 
Little Chalfont, UK) with NaCl gradient. Purified human HRG was identified by sodium dodecyl 




EA.hy 926 cells or HMVEC cells were pretreated with various concentrations of HRG or 
human serum albumin (HSA) for 1 h before stimulated with LPS (Escherichia coli 0111:B4, Sigma) 
(25–200 ng/ml) or human recombinant HMGB1 (rHMGB1, Abnova, Taiwan) (1 μg/ml). The cells 
were then fixed with 4% paraformaldehyde (Wako Pure Chemical Industry, Osaka, Japan) and 
blocked with 10% bovine serum albumin (BSA), after which the cells were stained by anti-HMGB1 
Ab (rabbit, Sigma, RRID:AB_444360), anti-NF-κB p65 Ab (rabbit, Abcam, RRID:AB_443394), 
anti-ICAM-1 Ab (Ms, Sigma, RRID:AB_445260), or anti-VCAM-1 Ab (#ab134047, Sigma, 
RRID:AB_2721053) for 1 h at 37°C followed by Alexa Fluor 488/568-labeled anti-rabbit/mouse 
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IgG. Cell nuclei were stained with DAPI for 5 min, and then observed using a confocal microscope 
(LSM 780, Carl Zeiss). 
 
Western blotting 
The whole cell lysate was collected with RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxylcholate, 0.1% SDS, 1 mM EDTA, 1 mM DTT, 20 mM β-
glycerophosphate, and protease/phosphatase inhibitors added immediately before use) and the 
cytoplasmic and nuclear extracts were collected with NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (#78833, ThermoScientific, Rockford, IL). The mice plasma sample was 
collected with sample buffer. All the samples were then electrophoresed on polyacrylamide gels 
and transferred onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA). The 
membrane was blocked with 10% skim milk for 1 h and incubated with rabbit anti-HMGB1 Ab (Rb, 
#ab18256, Sigma), anti-TLR2 Ab (Rb, #ab191458, Abcam), anti-TLR4 Ab (Rb, Abcam, 
RRID:AB_10561435), anti-CLEC 1 Ab (goat, #AF1704, RRID:AB_2083452), anti-HRG Ab (Rb, 
#GTX64492, Gen Tex ) and anti-β-actin Ab (#sc-47778, Santa Cruz, RRID:AB_2714189) followed 
by goat anti-rabbit IgG-HRP (MBL, Nagoya, Japan) for 2 h at room temperature. The signals were 
visualized by the enhanced chemiluminescence HRP substrate method (Thermo Fisher Scientific, 
Waltham, MA). An Image Quant LAS4000 system was used for detection, and images were 
analyzed with ImageJ software ver. 1.51. 
 
Cell viability 
EA.hy 926 cells were plated in 96-well plates at 5×105 overnight, and then pre-incubated with 
HRG/HSA for 1 h before stimulation with LPS (100 ng/ml) or rHMGB1 (1 μg/ml) for 8 h. The cells 
were then incubated with MTT at 37℃ for 4 h by adding 10 μl of 5 ng/ml MTT solution into each 
well. After the removal of the cell supernatant, 200 μl of DMSO was added into each well to 
dissolve the crystals. The absorbance of each well was measured using a microplate reader 
(model 680, Bio-Rad) at 570 nm wavelength, and the optical density (OD) value was recorded. 
 
Isolation of neutrophils  
Human neutrophils were isolated from peripheral blood obtained from healthy volunteers in 
accordance with ethics approval and guidelines of Okayama University and the Declaration of 
Helsinki. The blood was drawn from the antecubital vein. Human polymorphonuclear neutrophils 
(PMNs) were isolated by density gradient centrifugation over Polymorphprep™ (Axis-Shield, Oslo, 
Norway). Briefly, blood was layered over an equal volume of Polymorphprep and centrifuged at 
500 g for 45 min at 22°C. The lower band containing neutrophils was subsequently collected and 
washed with PBS by centrifugation at 400 g for 10 min. The cells were counted with a 
hemocytometer (EKDS, Tokyo) by trypan blue dye exclusion. After the centrifugation, the pellet 
was resuspended in Hank's balanced salt solution (HBSS). Purified human neutrophils were 
labeled with calcein-AM (green) and Hoechst 33342 (blue) for 20 min at 37°C and then washed 
once with PBS. Finally, the cells were resuspended in HBSS to a final concentration of 2×106 
cells/ml. 
 
Neutrophil adhesion assay 
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EA.hy 926 cell suspensions (5×105 cells/ml) were cultured in 96-well plates for 16 h until 
confluent for the cell adhesion assay. The monolayer was then washed with PBS and pretreated 
with HRG or HSA (1 μmol/L) for 1 h before being stimulated with LPS (100 ng/ml) or rHMGB1 (1 
μg/ml) at 37°C in a 5% CO2 atmosphere for 4 h. After the incubation, the cells were washed with 
PBS. The pre-labeled neutrophils (1×106 cells/ml) were then added to the stimulated endothelial 
monolayer and co-cultured for 1 h. The neutrophils were allowed to become adherent, and the 
nonadherent neutrophils were washed off. The fluorescence of the adherent cells was then 
measured. The percentage of adherent neutrophils was calculated as: the percentage of 
adherence = (adherent signal/total signal) ×100, as described (Bae et al., 2011). 
 
RNA isolation and RT-PCR 
EA.hy 926 cells or HMVEC cells were harvested and mRNA was extracted using an RNeasy 
mini kit (Qiagen). Complementary DNA was synthesized with a Takara RNA PCR kit ver. 3.0 
(Takara Bio, Nagahama, Japan) and RT-PCR was performed with a Light Cycler (Roche, Basel, 
Switzerland) according to the manufacturer's instructions. The primers shown in Supplemental 
Table S1 were used to amplify specific cDNA fragments. The β-actin expression was used to 
normalize the cDNA levels. 
 
Mice 
Adult male C57BL/6N mice (22±3 g, 8 week, RRID: MGI_5658420) were purchased from 
SLC (Hamamatsu, Japan) and then housed in the Okayama University institutional animal units 
(12 h light cycle). All animal experiments were approved by the university's committee and 
performed according to the guidelines of Okayama University on animal experiments. The 
C57BL/6N mice was intravenous injected of LPS (10 mg/kg) or recombinant HMGB1 (100 μg) 
and then HRG or HSA in vehicle (PBS) was administered through the tail vein immediately. Each 
mouse was given 20 mg/kg HRG or HSA in a volume of 200 μl (i.v.). After 12 h the whole blood 
from mouse heart were taken and used for the following experiment (Edward et al., 2000, Gao et 
al. 2019). 
 
Ezyme-linked Immunosorbent Assay (ELISA) 
To determine HMGB1 levels in plasma, blood samples were collected through the mouse 
heart under deep anesthesia, then centrifuged for 10 min at 3000 rpm. HMGB1 was detected by 
using an ELISA kit (Shino-Test Co, Sagamihara, Japan), according to the manufacturer’s 
instructions. 
 
Cytometric bead array (CBA) 
We measured the secreted cytokines in the supernatant of cultured medium or plasma form 
rHMGB1-injected mice by performing CBA using a Human Soluble Protein Master Buffer Kit and 
cytokine Flex Set (#558264, BD Biosciences, San Jose, CA) following the manufacturer's 
instructions. Generally, multiple capture beads for interleukin (IL)-6, IL-8, and TNF-α were mixed 
together. The mixed capture beads were co-incubated with 50 μl of supernatant and detection 
reagent for 2 h. The beads were then washed carefully and resuspended. Samples were analyzed 





We hypothesized that if we could force the secreted extracellular HRG to specifically 
concentrate on the cell surface at a much higher level, such abundant HRG on the plasma 
membrane will readily recognize and bind with its specific receptor(s). Based on this hypothesis, 
we designed HRG to express on the cell surface, resulting in the construction of modified HRG 
which we named membrane-anchored HRG (maHRG). This modified HRG has a single-pass 
transmembrane (TM) domain sourced from basal cell adhesion molecule (BCAM) at the C-
terminus of HRG protein. 
In order to efficiently express the transgenes that include maHRG and a set of candidate 
receptor molecules in a transient manner, we inserted cDNAs of our interest into the pIDT-SMART 
(C-TSC) vector (Sakaguchi et al., 2014). The prepared cDNAs were as follows: human cDNAs 
encoding maHRG and collected CLEC family receptors (CLEC-1A, -1B, -2A, -2B, -2C, -2D, -4A, 
-4C, -4D, -4E, -4F, -4G, -4M, -5A, -6A, -7B, -12A and -12B). The modified maHRG was further 
designed to be expressed in a C-terminal HA form. The CLEC receptors were all designed for 
their expression as C-terminal 3xFlag-6His-tagged forms. 
 
Immunoprecipitation 
We used HEK293T cells for the co-immunoprecipitation experiments. The cells were 
transiently transfected with the plasmid vector of maHRG combined with each vector containing 
a series of collected receptors, using FuGENE-HD (Promega, Madison, WI). After 24 h of the 
transfection, cell pellets were prepared and lysed by M-PER mammalian protein extraction 
reagent (Thermo Fisher Scientific). The lysates were then incubated with agarose beads 
conjugated with monoclonal anti-HA tag antibody (Sigma-Aldrich, St. Louis, MO) to pull-down the 
expressed maHRG. The resulting immunoprecipitates were subsequently subjected to western 
blotting using monoclonal anti-Flag tag antibody (Sigma-Aldrich) to detect maHRG-bound 
receptor candidate(s). 
 
Surface plasmon resonance analysis (BIAcore) 
The extracellular domain of CLEC-1A (exCLEC-1A)-Fc fusion protein was prepared from its 
corresponding conditioned media from cultures of a FreeStyle™ CHO-S cell (Chinese hamster 
ovary cell subline; Thermo Fisher Scientific)-derived stable clone. The stably expressed clone for 
exCLEC-1A-Fc was established by a convenient electroporation gene delivery method using our 
original pSAKA-1B vector as described (Kinoshita et al., 2019). After the collection of the serum-
free conditioned medium from a large-scale culture of the established CHO cell clone, 
recombinant exCLEC-1A-Fc protein was purified by protein-G affinity chromatography according 
to the manufacturer's instructions. 
We analyzed the binding affinity of exCLEC-1A-Fc fusion protein or human recombriant 
exCLEC-1A (1704-CL-050, R&D system) to HRG with the use of a BIAcore T200 instrument (GE 
Healthcare, GE Healthcare Life Sciences, Piscataway, NJ). First, HRG (5 μg/ml) diluted by sodium 
acetate buffer (pH 5.0) was immobilized on the sensor chip (Biacore sensor chip CM5). An 
adjacent vacant flow-cell was activated with equal amounts of 0.2 M N-ethyl-N-[3-diethylamino-
 12 
propyl]-carbodiimide and 0.05 M N-hydroxysuccinimide under the same conditions as a negative 
control. HBS-EP + buffer was used for the sample dilution and analysis. exCLEC-1A-Fc fusion 
protein at a series of concentrations (3.125, 6.25, 12.5, and 25 μg/ml) was passed over the 
surface sensor chip at a flow rate of 30 μl/min for 2 min, and then dissociation was allowed by the 
application of HBS-EP buffer. The sensor chips were regenerated by washing with 10 mM glycine-
HCl (pH 2.5) for 60 sec at a flow rate of 10 μl/min. 
We also analyzed the binding affinity of HRG to the immobilized exCLEC-1A-fc fusion protein. 
exCLEC-1A-fc fusion protein (10 μg/ml) diluted by sodium acetate buffer (pH 5.0) was immobilized 
on the sensor chip. Purified HRG (3.125, 6.25, 12.5, 25 and 50 μg/ml) was passed over the 
surface sensor chip at a flow rate of 30 μl/min for 2 min, and then dissociation was allowed by the 
application of HBS-EP buffer. The sensor chips were regenerated by washing with 10 mM glycine-
HCl (pH 2.5) for 60 sec at a flow rate of 10 μl/min. The results were calculated after the subtraction 
of the control values using BIAcore evaluation T200 software. 
 
Effects of HRG on neutrophils and EA.hy 926 cells after CLEC-1A blocking 
Prelabeled neutrophils were incubated with HBSS or HRG (0.25 μM) together with different 
concentrations of exCLEC-1A-Fc fusion protein or 10 μg/ml anti-human CLEC-1A or CLEC-1B 
goat polyclonal antibody (R&D Systems, Minneapolis, MN) for 1 h at 37°C. The shapes of the 
neutrophils were then observed under a fluorescence microscope. The cell shapes and cell sizes 
were analyzed by using an IN Cell Analyzer 2000 (GE Healthcare/Life Sciences, Tokyo) and IN 
Cell Analyzer Workstation software (GE Healthcare/Life Sciences) as described (Wake et al., 
2016). The form factor (max. dia./min. dia.) and the cell area were determined in each group. 
EA.hy 926 cells were pre-incubated with 10 μg/ml CLEC-1A Ab, CLEC1B Ab and goat 
polyclonal control IgG antibodies in DMEM medium for 6 h. The cells were then stimulated with 
LPS for 12 h in the presence or absence of HRG (1 μM). Immunostaining of HMGB1 and 
intercellular adhesion molecule (ICAM)-1 were performed as described above. 
 
Statistical analysis 
The data were analyzed with GraphPad Prism software ver. 6.01 (San Diego, CA). All values 
are presented as the mean ± SEM and were analyzed by an analysis of variance (ANOVA) 
followed by Bonferroni's test or post hoc Fisher test when the F statistic was significant. Probability 
(p) values <0.05 were considered significant. At least three independent experiments were 




Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW,  Youyi C,  Nahoko T, Kota 
A, Kazuhiko S., et al. (2019) exSSSRs (extracellular S100 soil sensor receptors) – Fc fusion 
proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis. Int J 
Cancer 144,3138–3145.  
Mori S, Takahashi HK, Yamaoka K, Okamoto M, Nishibori M. (2003). High affinity binding of serum 
histidine-rich glycoprotein to nickel-nitrilotriacetic acid: The application to microquantification. Life 
 13 
Sci 73,93–102. 
Sakaguchi M, Watanabe M, Kinoshita R, Kaku H, Ueki H, Futami J, Murata H, Inoue Y, Li SA, 
Huang P., et al. (2014). Dramatic increase in expression of a transgene by insertion of promoters 
downstream of the cargo gene. Mol Biotech 56,621–630.  
 
